EVMN
Evommune, Inc.
Last earnings -5.6% on 2026-05-07
$25.18
▲ +4.35%$25.18▲ +24.47%
over 1Y
L $15.01EODHDH $31.57
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.4%
1W+11.7%
1M+7.9%
3M+13.5%
YTD+45.5%
1Y+24.5%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 17 analysts
Strong Buy
Pre-revenue clinical-stage biotech with $44M cash against $76M annual burn — IPO'd Nov 2025, binary trial-readout bet at 65x sales.
Cash & equivalents $44.1M · FY2025
Evommune is a clinical-stage biotech that only began trading on the NYSE on November 6, 2025, and the financials make clear this is a research operation, not a business. FY2025 'revenue' of $13.0M is almost certainly collaboration/license income — the MD&A repeatedly flags the company's 'need to raise additional funding before we can expect to generate any revenues from product sales,' and the entire forward narrative hinges on two unapproved candidates, EVO756 and EVO301. Operating losses of -$81.1M on that $13.0M base produce a nonsensical -624% operating margin, and R&D alone ($74.0M) is nearly 6x revenue. The -$221M accumulated deficit confirms this is a cash-burn story from inception.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | $7.00M | $13.0M |
| Gross profit | — | — |
| Operating income | -$70.0M | -$81.1M |
| Net income | -$66.8M | -$68.9M |
| Diluted EPS | -$45.29 | -$11.22 |
| Net margin | -954.4% | -529.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$863M
EV / EBITDA—
EV / Sales66.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.6%
FCF yield-8.5%
Quality & risk
ROIC (est.)-31.2%
Free cash flow-$76.7M
Total debt—
Net cash$44.1M
Altman Z-Score26.29 safe
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Shareholder vote2026-06-02
Annual meeting vote results disclosed; routine governance, no operational impact.
- 8-K Earnings results2026-05-07
Q1'26 10-Q: cash burn continues on EVO756/EVO301 development, no commercial revenue.
- 10-Q Quarterly report2026-05-07
Q1'26 10-Q: cash burn continues on EVO756/EVO301 development, no commercial revenue.
- DEF 14A Proxy statement2026-04-21
Definitive proxy for annual meeting; routine governance and comp disclosures.
- S-1 Securities registration2026-04-17
New S-1 post-IPO signals follow-on or insider resale registration; dilution overhang.
- 8-K Reg FD disclosure2026-04-13
Reg FD disclosure with exhibit, likely investor/medical conference presentation.
- 8-K Earnings results2026-03-05
First 10-K as public co: $44M cash, $76M op burn, lease expansion signals scale-up.
- 10-K Annual report2026-03-05
First 10-K as public co: $44M cash, $76M op burn, lease expansion signals scale-up.
- 8-K Material agreement2026-02-13
Material agreement + unregistered equity sale: PIPE/financing raises cash but dilutes.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗144Filing2026-06-22open ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗144Filing2026-06-02open ↗424B3Filing2026-06-02open ↗8-KPeriod ending 2026-06-022026-06-02open ↗
Frequently asked
- Is Evommune, Inc. (EVMN) a buy?
- EVMN currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue clinical-stage biotech with $44M cash against $76M annual burn — IPO'd Nov 2025, binary trial-readout bet at 65x sales.
- What is Evommune, Inc.'s quality score?
- EVMN scores 42.05882352941176/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002044725, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 2:41:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.